Waldenström's Macroglobulinemia

Anita D'Souza; Morie A. Gertz

doi:10.1002/9781118589199.ch58

Waldenström's Macroglobulinemia

Anita D'Souza, Morie A. Gertz

Hematology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter presents a series of multiple choice questions and answers and case studies on Waldenström's macroglobulinemia (WM). It commences with a discourse on WM. The chapter talks about the genetic changes associated with WM, response to treatment measured, and different standard and novel therapies in WM. It analyzes whether autologous stem cell transplantation should be a front-line option. The chapter concludes with a discussion on cryoglobulinemia and related autoimmune disorders in WM. Risk of amyloid light-chain (AL) amyloidosis, immunoglobulin M (IgM)-related neurologic manifestations and survivorship issues in W4M are also discussed.

Original language	English (US)
Title of host publication	Cancer Consult
Subtitle of host publication	Expertise for Clinical Practice
Publisher	Wiley-Blackwell
Pages	371-375
Number of pages	5
ISBN (Electronic)	9781118589199
ISBN (Print)	9781118589212
DOIs	https://doi.org/10.1002/9781118589199.ch58
State	Published - Jun 20 2014

Keywords

Allogeneic stem cell transplantation
Amyloid light-chain (AL) amyloidosis
Autologous stem cell transplantation
Cryoglobulinemia
W4M
Waldenström's macroglobulinemia (WM)

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118589199.ch58

Cite this

@inbook{173a95b9dca14beb8fd57b46419f1d9a,

title = "Waldenstr{\"o}m's Macroglobulinemia",

abstract = "This chapter presents a series of multiple choice questions and answers and case studies on Waldenstr{\"o}m's macroglobulinemia (WM). It commences with a discourse on WM. The chapter talks about the genetic changes associated with WM, response to treatment measured, and different standard and novel therapies in WM. It analyzes whether autologous stem cell transplantation should be a front-line option. The chapter concludes with a discussion on cryoglobulinemia and related autoimmune disorders in WM. Risk of amyloid light-chain (AL) amyloidosis, immunoglobulin M (IgM)-related neurologic manifestations and survivorship issues in W4M are also discussed.",

keywords = "Allogeneic stem cell transplantation, Amyloid light-chain (AL) amyloidosis, Autologous stem cell transplantation, Cryoglobulinemia, W4M, Waldenstr{\"o}m's macroglobulinemia (WM)",

author = "Anita D'Souza and Gertz, {Morie A.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley and Sons, Inc.",

year = "2014",

month = jun,

day = "20",

doi = "10.1002/9781118589199.ch58",

language = "English (US)",

isbn = "9781118589212",

pages = "371--375",

booktitle = "Cancer Consult",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Waldenström's Macroglobulinemia

AU - D'Souza, Anita

AU - Gertz, Morie A.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - This chapter presents a series of multiple choice questions and answers and case studies on Waldenström's macroglobulinemia (WM). It commences with a discourse on WM. The chapter talks about the genetic changes associated with WM, response to treatment measured, and different standard and novel therapies in WM. It analyzes whether autologous stem cell transplantation should be a front-line option. The chapter concludes with a discussion on cryoglobulinemia and related autoimmune disorders in WM. Risk of amyloid light-chain (AL) amyloidosis, immunoglobulin M (IgM)-related neurologic manifestations and survivorship issues in W4M are also discussed.

AB - This chapter presents a series of multiple choice questions and answers and case studies on Waldenström's macroglobulinemia (WM). It commences with a discourse on WM. The chapter talks about the genetic changes associated with WM, response to treatment measured, and different standard and novel therapies in WM. It analyzes whether autologous stem cell transplantation should be a front-line option. The chapter concludes with a discussion on cryoglobulinemia and related autoimmune disorders in WM. Risk of amyloid light-chain (AL) amyloidosis, immunoglobulin M (IgM)-related neurologic manifestations and survivorship issues in W4M are also discussed.

KW - Allogeneic stem cell transplantation

KW - Amyloid light-chain (AL) amyloidosis

KW - Autologous stem cell transplantation

KW - Cryoglobulinemia

KW - W4M

KW - Waldenström's macroglobulinemia (WM)

UR - http://www.scopus.com/inward/record.url?scp=84946429497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946429497&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch58

DO - 10.1002/9781118589199.ch58

M3 - Chapter

AN - SCOPUS:84946429497

SN - 9781118589212

SP - 371

EP - 375

BT - Cancer Consult

PB - Wiley-Blackwell

ER -

Waldenström's Macroglobulinemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this